VivoSeq
Oncology

Cutaneous Squamous Cell Carcinoma (CSCC)

2

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Cutaneous Squamous Cell Carcinoma (CSCC) is an early-stage landscape with 2 programs across 2 companies. The most active players are Ankyra Therapeutics, Inc, Regeneron. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

0/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Ankyra Therapeutics, Inc

1 program

Phase 1Regeneron logo

Regeneron

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Tolododekin Alfa

Ankyra Therapeutics, Inc

Phase 2
No programs
Phase 31

Cemiplimab

Regeneron

Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Monoclonal antibody150%

Modality classified for 100% of 2 pipeline programs.

Analysis

Trial Status

3

clinical trials

Recruiting1 · 33%
Not yet recruiting1 · 33%
Withdrawn1 · 33%

Clinical Trials

Trial Activity

A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC)
Recruiting·Regeneron logoRegeneron·Phase 3·NCT06585410·369 enrolled
D-TECT: Prospective Multicenter Evaluation of Pretreatment D-dimer Levels as a Predictor of Disease Control in Advanced Cutaneous Squamous Cell Carcinoma Treated With Cemiplimab
Not yet recruiting·UUniversitätsklinikum Hamburg-Eppendorf·N/A·NCT07684066·116 enrolled
An Open-Label Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With Resectable, High-Risk Cutaneous Squamous Cell Carcinoma
Withdrawn·AAnkyra Therapeutics, Inc·Phase 1·NCT07100925

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)